New treatment for eye surface inflammation
Immunotherapy for Ocular Surface Diseases
['FUNDING_OTHER'] · UNIVERSITY OF ILLINOIS AT CHICAGO · NIH-11020997
This study is looking at how certain immune responses might be causing inflammation in people with dry eye disease, and it’s testing new eye drops that could help reduce that inflammation and improve your symptoms.
Quick facts
| Phase | ['FUNDING_OTHER'] |
|---|---|
| Study type | Nih_funding |
| Sex | All |
| Sponsor | UNIVERSITY OF ILLINOIS AT CHICAGO (nih funded) |
| Locations | 1 site (Chicago, UNITED STATES) |
| Trial ID | NIH-11020997 on ClinicalTrials.gov |
What this research studies
This research investigates a novel mechanism of inflammation in patients with dry eye disease (DED) by examining the role of neutrophil extracellular traps (NETs) and anti-citrullinated protein antibodies (ACPAs). The study aims to develop a new treatment using ocular surface immune globulin (OSIG) eye drops, which have shown promise in initial trials for reducing inflammation and improving symptoms in DED patients. By understanding the autoimmune processes involved, the research seeks to shift the treatment paradigm towards addressing these underlying causes. The ultimate goal is to gather preclinical data to support an application for FDA approval of this new therapy.
Who could benefit from this research
Good fit: Ideal candidates for this research are individuals diagnosed with dry eye disease who experience chronic inflammation of the ocular surface.
Not a fit: Patients with other forms of eye diseases unrelated to dry eye or those without autoimmune components may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could provide a new, effective treatment option for patients suffering from dry eye disease.
How similar studies have performed: Other research has indicated success in using immune globulin therapies for autoimmune conditions, suggesting potential for this novel approach in treating dry eye disease.
Where this research is happening
Chicago, UNITED STATES
- UNIVERSITY OF ILLINOIS AT CHICAGO — Chicago, UNITED STATES (ACTIVE)
Researchers
- Principal investigator: JAIN, SANDEEP — UNIVERSITY OF ILLINOIS AT CHICAGO
- Study coordinator: JAIN, SANDEEP
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.